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“The most intelligent men, like the strongest, find their happiness 
where others would find only disaster: in the labyrinth, in being hard 
with themselves and with others, in effort; their delight is in self-
mastery; in them asceticism becomes second nature, a necessity, an 
instinct. They regard a difficult task as a privilege; it is to them a 









If I have seen further, it is by standing on the shoulders of Giants. 





POPULAR SCIENCE SUMMARY OF THE THESIS 
 
Physical injuries after accidents or violence are a major cause of death worldwide in both 
civilian societies and armed conflicts, especially among children and young adults. Massive 
bleeding is an important cause of possibly preventable deaths after physical injuries and needs 
to be managed in the acute phase of patient care. External bleeding can often be controlled by 
compression of the wound or by using adjuncts for decreasing the blood flow to the site of 
injury. Such devices are called tourniquets, derived from the French word tourner – “to turn”. 
However, these methods for control of bleedings are principally limited to extremity wounds. 
Internal bleedings in the abdomen and pelvis are often associated with significant blood loss 
and cannot be compressed by manual force or standard tourniquets. Furthermore, severe tissue 
injury has been shown to cause systemic reactions on a molecular level that can further 
aggravate blood loss due to dysfunctions in the ability to form stable blood clots – this involves 
both the process of coagulation, and fibrinolysis which is the resolve of a clot. This is referred 
to as Trauma Induced Coagulopathy (TIC). Coagulation dysfunction is an individual and 
important factor for mortality after physical injuries. The specific causes for the development 
of TIC remains unknown but involves many different sources that needs to be discovered and 
preclinical research, using animal models, are needed for further understanding of this process. 
Methods for early, specific, assessment of the bloods ability to form stable blood clots can 
provide information needed to develop treatments to increase survival after injury and surgery 
(which is often needed to obtain definitive bleeding control). Therefore, early interventions for 
prevention of massive blood loss and detection methods for specific dysfunctions in the 
coagulation system may have a significant impact on mortality and functional outcome after 
severe injuries. 
Novel methods have been developed for the possibility to mechanically control or limit 
hemorrhage from non-compressible sources. These include a device for external compression 
of the abdominal aorta (Abdominal aortic and Junctional Tourniquet, AAJT) and a method for 
occluding aortic blood flow using an inflatable balloon inside the vessel (Resuscitative 
Endovascular Balloon Occlusion of the Aorta, REBOA). However, these interventions can be 
dangerous because of their dramatic circulatory effects and the decreased exchange of oxygen 
and cellular byproducts from the tissues distal to the occluded blood flow - so called ischemic 
injuries. Animal studies targeting the effectivity and specific harmful effects of the AAJT and 
REBOA can provide important knowledge regarding safe application-time limits and specific 
management strategies, including the removal of the devices. As for TIC, a robust animal 
model with methods for induction of TIC and detection of the specific components of 
coagulation dysfunction after trauma is needed for future studies on treatment options.   
The overall aim of this thesis was to provide physiological animal data on the above mentioned 
novel mechanical hemostatic adjuncts to facilitate their implementation into clinical practice 
(translational research) and to contribute to the important research area of traumatic 
coagulopathy. All studies in the present thesis was conducted on pigs averaging 60 kg because 
of the similarities in anatomical dimensions as well as physiological likeness in cardiovascular 
function, response to hemorrhage shock and pharmacological therapies.  
In study I, we investigated the physiological consequences of an abdominal aortic tourniquet 
in relation to a 60- versus 240-minute application time and compared the resuscitative effects 
to standard fluid resuscitation. We found that the device effectively stopped blood flow at the 
level of the abdominal aorta with sustained circulation to the kidneys and thus show potential 
as a hemostatic device for control of bleeding from distal injuries. However, the mechanical 
compression caused significant injuries to the intestine and liver after 240 minutes but not after 
60 minutes. The abdominal tourniquet also produced an increased blood pressure and therefore, 
less un-physiologic fluids were needed to restore and maintain blood circulation of the heart, 
lungs and brain in the animals.  
In study II, we compared the circulatory resuscitative effects, and the total need for clear fluids 
(Ringer´s acetate), i.e. non-blood products, between the abdominal aortic tourniquet device and 
REBOA with the balloon placed in the abdominal aorta between the kidney branches and the 
division of the aorta into the inguinal arteries (zone III). We found a significantly higher need 
for resuscitation fluids to restore and maintain circulation of the organs above the aortic 
occlusion with REBOA compared to the AAJT. These findings indicate that the AAJT, which 
is also easier to use by non-medical professionals, may be more suitable in the first phase of 
care in the field. This study also implicated a lesser physiological penalty with zone III REBOA 
compared to the AAJT.  
In study III, we investigated the possibility to replace the AAJT with zone III REBOA because 
of the possibility to operate a patient during REBOA which cannot be done with the AAJT in 
place on the abdomen. The findings in study II, of a possibly longer physiological tolerance of 
zone III REBOA also implicated this study. We found that a transition between these 
interventions can be performed, but may be technically challenging due to the decreased 
diameter of the femoral artery (which is used for insertion of the REBOA balloon catheter) 
after blood loss and AAJT application. Furthermore, in line with the findings in study I, a 
 
 
decrease in blood pressure occurred after the transition procedure which required blood volume 
replacement and/or drugs for constriction of the blood vessels to maintain a sufficient blood 
pressure.   
In study IV, we investigated a strategy of a zone I (thoracic) REBOA balloon inflation for 10 
min followed by complete deflation for 3 min during 60 minutes’ total intervention time. 
Placement of the balloon in the thoracic aorta may be needed to control bleedings in the 
abdomen and to restore circulation in patients with extremely low blood pressure. Previous 
studies have found that thoracic aortic occlusion (close to the heart) may risk cardiac injury 
because of the high mechanical resistance towards the cardiac output. Study IV was designed 
to evaluate the possibility to mitigate the ischemic injury associated with REBOA, by permit 
intermittent circulation (hence the term intermittent REBOA) and partial oxygenation of the 
body regions that becomes uncirculated during REBOA. Furthermore, we studied the 
relationship between blood flow in the aorta (as restored by the balloon deflation) and the major 
kidney arteries and found that these did not correlate directly. The findings in study IV 
implicated that intermittent release of the high resistance close to the heart may decrease the 
risk of cardiac injury during 60 min intervention. We also showed that the low-grade return of 
circulation of the kidneys, during the balloon deflation intervals, resulted in superior urine 
production which may be viewed as a predictor of decreased risk for kidney injury after 
REBOA. The intermittent REBOA protocol was, however, associated with large fluctuations 
in blood pressure and the 3 minute deflations had to be aborted increasingly often due to 
dangerously low blood pressure.  
In study V, we addressed the development of an animal model that can be used for further 
studies in the process of acute traumatic coagulopathy. We designed a research model which 
included two different physical injury modalities, massive bleeding, low body temperature and 
dilution of the blood with clear fluids which is also associated with coagulation dysfunction. 
We used a test called rotational thromboelastography, often used in human patients, which can 
discover a variety of coagulation abnormalities. With this method, a summarization of all 
components in the bloods function of coagulation and fibrinolysis is visually presented. We 
further added a mathematical method, called principal component analysis, which allowed for 
multiple comparisons between individual animals and the different trauma modalities at 
specific time points. We were able to induce TIC and further to detect specific differences 
between the study groups and therefore this study showed promising results for future studies 
in this area.  
In general, prospectively collected data from human patients are needed to advance the 
possibility to use these novel mechanical hemostatic adjuncts in clinical scenarios and further 
























Trauma, in terms of physical injury, is the leading cause of death and disability among children 
and young adults worldwide. Hemorrhage and coagulation dysfunction are two important 
causes of preventable deaths after traumatic injuries. Novel methods for management of non-
compressible hemorrhage and treatment of trauma induced coagulopathy (TIC) may reduce 
mortality. In this thesis we investigate two fundamentally different methods for mechanical 
hemorrhage control after potentially lethal truncal hemorrhage: intravascular occlusion- and 
external compression of the aorta. The Abdominal Aortic and Junctional Tourniquet® (AAJT) 
and Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) were initially 
introduced in military medicine as possible interventions to avoid exsanguination from large 
vessel injuries. We assessed these interventions during 60 to 240 minutes with the aim to 
identify specific physiological effects and suggest tolerable application times. The feasibility 
of a transition between the methods was studied. We investigated the hemodynamic effects of 
crystalloid- and whole blood transfusion in conjunction with the interventions. Intermittent 
reperfusion during REBOA, with the aim to decrease organ damage was investigated. We 
introduced a method for advanced analyzation of viscoelastic tests by principal component 
analysis to detect TIC. The AAJT and REBOA were both effective to stop hemorrhage distal 
to the aortic bifurcation and restored critical circulation proximal to the aortic occlusion. Infra-
renal REBOA required more crystalloid fluids to restore the circulation than AAJT. Both 
methods caused ischemic injuries which became significant after 1 hour of infra-renal aortic 
occlusion. The ischemic injuries were alleviated by intermittent reperfusion during thoracic 
REBOA application. TIC was detected in pigs by principal component analysis of rotational 
thromboelastometry, which comprised a new method for possible identification of TIC 
phenotypes.  In conclusion, mechanical hemostasis was effective by both abdominal 
tourniquet- and intravascular aortic occlusion. We also identified potentially severe 
complications due to hemodynamic- and metabolic consequences, particularly when 
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Traumatic injuries are the leading cause of death among children and middle-aged adults 
worldwide and constitutes approximately 10% of total mortality in all ages (1). More than 12 
000 people die each day from injuries as a result of accidents or violence (1).  In perspective, 
the number of deaths caused by trauma (in this thesis defined as physical injury) is around 1.7 
times higher than the overall deaths of the infectious diseases AIDS, malaria and tuberculosis 
combined (2). The global mortality as a result of conflicts and terrorism is approximately 
130 000 each year, or approximately 15 people every hour (1). Survival, clinical- and 
functional outcomes after severe injuries is highly dependent on the quality of, and timely 
access to adequate care. The Birmingham Accident Hospital, founded in the UK 1941, is 
considered as the first medical facility dedicated to trauma-victims and the start of a medical 
evolution leading to today’s modern trauma-centres (3). Reflecting upon the time for the 
foundation of this first trauma-hospital, it must be noted that, sadly, a substantial amount of the 
knowledge foundation for the care of trauma-victims have been congregated during times of 
war. Recognizing the impact of early, life-saving interventions and transferral to definitive care 
- in 1966, the National Academy of Sciences in the US,  published  “Accidental Death and 
Disability: The neglected disease of modern society” (4). That report influenced the 
development of the first prehospital emergency medical services, as an integrated part of a 
regional trauma system.  
Figure 1. Major causes of global deaths (2017) in ages 1-49 years.  
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Hemorrhage is the most important cause of deaths that possibly could have been prevented 
after trauma (5-7). It accounts for approximately 30-40% of deaths following injuries every 
year, of which 50% occurs outside hospitals. In a Swedish report investigating injury-related 
mortality, the vast majority (90%) died before hospital admission. Furthermore, the injury 
characteristics differed significantly from the hospital deaths including firearm injuries where 
67% of deaths occurred prehospital (8). Analyses of prehospital deaths in military (7) and 
civilian trauma (8) show similarities with a majority of deaths regarded as nonsurvivable. 
However, of the potentially survivable deaths on the battlefield up to 91% are related to 
hemorrhage (9-11). This thesis is largely based on studies conducted in military populations. 
Considerable research- and clinical efforts the past two decades have resulted in unprecedented 
improvements in mortality rates of combat casualties (12). These determinations are paving the 
way for the management of severely injured patients in civilian trauma as well, especially 


















2 LITERATURE REVIEW 
 
2.1 MILITARY INJURY PATTERNS IN RELATION TO CIVILIAN TRAUMA 
Understanding the causes of death after traumatic injuries is fundamental for research and 
development of new treatments as well as the organization of trauma-systems. In 1996, Tactical 
Combat Casualty Care (TCCC) (13) was introduced in the US military as a result of a 2-year 
study identifying casualty care techniques with more appropriateness than the previously used 
principles of Advanced Trauma Life Support (ATLS) (14), adopted from the civilian care. The 
need for these modifications were based on the combined complexity of severe injuries from 
high energy-  and blast trauma, limited medical equipment, hostile environments, inconstant 
evacuation times and a high proportion of penetrating trauma. The TCCC concept has since 
been continuously revised and updated in accordance with evidence based, proposed changes. 
In 2010, after ten years of war in Iraq and Afghanistan, the outcomes after severe combat 
injuries where equal to, or better than those in the US civilian trauma systems (15). Still, a 24% 
of battlefield mortalities has been deemed as potentially survivable (7).  
Figure 2. Aetiology of potentially salvageable combat fatalities 2001-2011(7).  
 
The most common causes of deaths, that were judged as non-survivable and occurred instantaneously or in the 
acute phase after injury were: brain injury (43%), heart/thoracic injury (21%), dismemberment (16%), other 
(13%), open pelvic injury (3%) and high spinal cord injury (4%).  
In the subgroup of patients who die from hemorrhage but have been regarded as potentially 
survivable (80%) (16), the term “exsanguination shock” has been introduced to further 

















multiple organ failure in later stages of hemorrhage shock (17). These patients typically present 
severe hypotension or even arrest due to massive blood loss, but respond to resuscitation and 
surgical hemostasis before passing away. The underlying pathophysiology behind death in 
these patients is unknown but likely involves complex molecular dysregulation after profound 
ischemia, and as a result of inflammation, oxygen debt, coagulation dysfunction, CNS 
dysfunction and immune-related mechanism with capillary occlusion (17).  Furthermore, 
respiratory arrest rather than circulation failure is often the first sign of deterioration.  
Penetrating injuries from explosive fragments or gunshot wounds can be expected in up to 75% 
of casualties in combat (7, 18). These injuries often involve vascular- or solid organ disruption 
(19) which can lead to rapid external or intra-cavital, fatal loss of circulating blood volume 
(exsanguination) following the rationale of Poiseuille´s law – the larger the vessel, the greater 
the blood flow (20, 21). Massive hemorrhage from intra-abdominal or thoracic sources are 
historically only amendable for surgical control due to the severity to manually exert counter 
pressure against the injury site. Hence, the term non-compressible hemorrhage (NCH). 
Figure 3. A “pressure-plate” improvised explosive device found buried in a road in Afghanistan before it could 
do harm.  
 
Injuries caused by explosive ordnance has increased significantly in recent wars in Afghanistan and Iraq and is 
the most common (72%) mechanism of injury (18). Photo: Personal stock.  
To date, no formal definition of NCH exists allowing for comparisons of epidemiology and 
treatments. However, the concept includes vascular disruption with hemorrhage from ruptured 
vessels or solid organs in the abdomen and thorax including the pelvis and junctional regions 
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between the proximal extremities and the torso (22, 23). In particular, bleeding from the lower 
trunk and pelvic regions poses a great opportunity for reduction of mortality rates in rural 
civilian and military environments (7, 24). Analyses of data between 2002-2010 of the 
frequency and mortality of NCH (further categorized to anatomical subgroups of thoracic, 
solid-organ, axial vessels and pelvic fractures) in Iraq and Afghanistan summarized that 13.7% 
of all injuries were classified as torso injuries with a mortality rate of 19% (16).  In the civilian 
environment, similar figures of frequency and mortality exists but with a majority of blunt 
rather than penetrating mechanisms of trauma (25). The injury patterns in the military 
population with up to 90% penetrating trauma and a significant need for massive transfusions 
(>10 units of packed red blood cells (RBCs) (26), encouraged the development of a 
resuscitation strategy more specifically targeting the physiological consequences of severe 
blood-loss and profound hypoperfusion.  
Figure 4. Anatomic focus of potentially survivable hemorrhage-related deaths on the battlefield 2001-2010(11). 
 
The development of body armour effectively protecting thoracic organs have increased the ratio of potentially 
preventable deaths from lower abdominal, pelvic and inguinal combat related injuries.  
 
2.2 HEMORRHAGE SHOCK AND TRAUMA INDUCED COAGULOPATHY (TIC) 
The relationship between blood loss and hemorrhage shock was first described in animal 
experiments performed by Blalock in 1930 (27). Shock occurs during inadequate oxygen 
delivery or utilization in peripheral tissues and develops secondary to a circulatory failure (28). 
Blood loss will lead to hypovolemic shock when the venous return decreases below the 
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of approximately 65 mm Hg (29). The pathophysiology of shock can be understood as 
insufficient aerobic energy production and a developing oxygen debt (30). The standard 
metabolic variable for detection and quantification of  anaerobic glycolysis from imbalance 
between oxygen delivery (DO2) and demand (VO2) is lactate (31, 32). Hyperlactatemia is 
generally defined as blood lactate levels > 1.5-2 mmol/L and has been shown as a reliable 
predictor of outcome in practically all types of circulatory shock (33, 34). However, important 
exceptions exists, for example a prompt elevation of lactate levels may reflect as a part of 
reperfusion of hypoxic tissue and thus a step towards clinical improvement (35). To avoid 
extensive cell death and organ damage, the perfusion must be restored and the oxygen debt 
compensated (36). The degree of blood loss  may not reflect the susceptibility to shock due to 
physiological differences (such as cardiac performance, capillary density and mitochondrial 
concentration- and function) in DO2 or VO2,  (30, 36, 37) and therefore hypotension is not an 
obligate criteria in the diagnosis or definition of clinical shock (38). Signs of shock is 
characteristically often presented as tissue hypo-perfusion which can be revealed through the 
three “windows of the body” by cold, damp and discoloured peripheral skin, low or absent 
urine production and affected mental status  (39). Blood loss is offset by sympathetic-mediated, 
and hormonal compensatory mechanisms, such as cardiovascular adaptations and 
hyperglycaemia (which osmotically recruits extravascular body-water into the circulation) to 
uphold critical organ perfusion. Therefore, blood pressure changes after hemorrhage shows a 
non-linear relationship to blood-loss up to a point where these mechanisms are depleted. As a 
consequence, hemorrhage with manifest hypotension, may reflect a severe grade of blood loss 
and ongoing development of profound hemorrhage shock, especially in young and otherwise 
healthy individuals. In trauma populations with clinical signs of hypoperfusion, hemorrhage 

















Adopted from the ATLS student course manual, tenth edition (40). 
Severe traumatic injury is now known to cause massive endogenous reactions on a molecular 
level. Changes in expression of up to 75% of the genome has been reported as a response to 
severe injury (a “genomic storm”) with crucial impact on immunologic and inflammatory 
pathways (41). Coagulation dysfunction is present in at least 25% of severely injured patients 
(depending on the definition used) upon hospital admission (42) and constitutes a major, 
independent cause of mortality (43, 44). The understanding of coagulopathy associated with 
trauma have recently evolved from an iatrogenic condition sprung from deranged homeostasis 
(acidosis and hypothermia) and loss of effective coagulation factors due to hemodilution (45). 
Recent knowledge suggests that the process of acute traumatic coagulopathy (ATC) more 
importantly arises as an endogenous condition in the presence of tissue injury and hemorrhage 
shock and that this onsets as early as minutes after injury (42, 46-48). The concept of ATC 
involves both disrupted plasma coagulation (the crucial part of fibrin mediated stabilization of 
blood-clots secondary to primary hemostasis by vasoconstriction and formation of platelet 
plugs) and fibrinolysis (49). The pathogenesis of ATC is multifactorial, however, to a large 
degree not understood. It is generally believed that the activated protein C (aPC) pathway is a 
central part of the pathologic condition of ATC (50). Translational research plays a 
fundamental role in the search for the mechanisms behind the pathogenesis of ATC and 
potential treatment options. The traditional assays for detecting ATC are prothrombin time 
(PT), activated partial thromboplastin time (aPTT) and international normalized ratio (INR), 
using a 50% increase in these parameters as a diagnostic criteria (51). These tests are limited 
by the low concentration of, and only measuring the initial function (30-60 s) of, the platelets 
and the laboratory delay in the situation of acute and often time-sensitive management of 
Class I II III IV 
Hemorrhage (%) < 15 15-30 30-40 > 40 
Heart-rate Unchanged > 100 > 120 > 140 
Arterial pressure Unchanged Unchanged Decreased Very low 
Capillary refill Unchanged Delayed Slow None 
Breathing rate Unchanged High normal Tachypnea Distinct Tachypnea 
Mental status Unchanged Uneasy Disoriented Lethargic 
Urine output Unchanged 15-30 mL/h < 20 mL/h None 
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trauma patients. Viscoelastic tests such as thromboelastography and rotational 
thromboelastometry (ROTEM) reflecting a more global coagulation performance of the blood 
at the bedside has therefore been introduced but no general diagnostic criteria of ATC using 
viscoelastic tests are currently adopted. 
 
2.3 ASPECTS OF FLUID RESUSCITATION AND USE OF BLOOD IN 
TRAUMATIC HEMORRHAGE 
It is well known that resuscitation using fluids and transfusion of blood products may be 
necessary to resuscitate a hypovolemic patient (52). The golden questions in resuscitation are 
when, what type of and to what degree administration of fluids should be performed (53, 54). 
Furthermore, the preferential use of isotonic crystalloid- versus hypertonic colloid fluids has 
been debated for many years (55). Sodium, constituting the principal osmotic factor in 
crystalloid solutions, will distribute along the concentration gradient across capillary 
membranes and thus, the main part of administered fluids (75-80%) will follow to the 
extravascular space within approximately one hour, which in turn leads to loss of circulating 
volume and (with excessive administration) formation of oedema (56, 57). Colloids on the 
other hand, contains osmotic molecules designed to remain intravascular and expand the 
circulating volume for up to 8 hours (58). In prehospital environments there is a consensus that 
fluids (any) should be administered in bleeding patients with signs of deteriorated mental status, 
reflecting an insufficient perfusion of the brain, and thus, end-state hypovolemia (52).  
In the early -90s, the ATLS protocol advocated liberal use of crystalloid fluids (2000 mL as 
soon as possible) to normalize blood pressure (59). That strategy has subsequently been proven 
to be harmful in patients where hemorrhage control is not obtained, due to risk of worsened 
bleeding and coagulation dysfunction, which in turn is due to hypothermia and dilution of 
coagulation factors and oxygen carrying haemoglobin (60-62). Animal data has shown survival 
benefits with permissive hypotensive resuscitation to 20 mm Hg below baseline MAP over 
resuscitation to baseline values and restraining of fluids until after surgical hemorrhage control 
(63). The damage control resuscitation (DCR) strategy was introduced in military medicine in 
2007 as a response to the increased understanding of injury patterns and causes of mortality of 
the casualties. In this concept the targeted systolic blood pressure (SBP) during initial fluid 
resuscitation is around 80-90 mm Hg, using plasma and RBCs in a ratio of 1:1 or as close 
relation as possible (64, 65). This strategy is now also advocated by prestigious civilian 
hospitals like the Mayo Clinic in the US (66). During the following years, the sentience of 
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appropriateness of replacing lost blood with whole blood was growing and several studies 
provided evidence of this being correct (67-70). The use of fresh whole blood has further been 
shown to improve outcome in comparison with component therapy, which partly may be 
attributed to the mechanic properties of the red blood cells and their capillary interaction (69). 
Of course, several logistical and potential medical risks limit the use of fresh whole blood both 
in the prehospital and hospital settings. The possibility to perform comparability tests to avoid 
allergic transfusion reactions, storage (more than a few days) and screening for transmittable 
diseases are the major limitation factors for the use of fresh whole blood in emergency 
situations outside hospitals. Since administration of whole blood or blood-products (fresh 
plasma, RBCs and platelets) is foremost a logistical problem in the military prehospital 



















Figure 5. A medic during World War II infusing plasma to a wounded soldier.  
 
Resuscitation with blood products was used before the era of synthetic fluids. During the Vietnam-war, crystalloids 
was the principally used resuscitation fluid, often excessively, which led to the encounter of their potentially 
harmful effects. Hence the word “shock-lung” or “DaNang Lung” which refers to the formation of pulmonary 
oedema and respiratory failure after successful hemodynamic resuscitation with voluminous administration of 
crystalloids. Photo from U.S. Army Medical Department Office of Medical History Website. Reproduced with 
permission.  
 
2.4 HEMORRHAGE CONTROL AFTER SEVERE INJURY 
In modern history, treatment of severe traumatic hemorrhage have improved despite the lack 
of novel revolutionary means to achieve early control of bleeding. Extremity bleedings can be 
controlled with manual wound pressure, proximal control using tourniquets, and hemostatic 
agents (72-74). These interventions are principally limited to extremity injuries. 
Immobilisation of long bone fractures and the pelvis reduces blood loss from venous and bone-
fracture-surface bleedings by counteracting mechanical disturbance of clot-formation. 
Pharmacological treatment including early administration of anti-fibrinolytic agents 
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(administered within 3 h of injury) (75, 76), coagulation proteases (77), reversal of oral 
anticoagulants (78) and antibiotics are also a part of the clinical management of patients with 
massive traumatic hemorrhage.  
Rapid hospital transfer is the most important factor to improve survival after massive NCH. 
Traditionally, the in-hospital treatment of intra-abdominal hemorrhage, in the presence of 
profound hemorrhage shock, is thoracic aortic occlusion by means of thoracotomy (79). This 
procedure can provide temporary control of bleeding and increase cerebral and coronary 
perfusion. However, the outcomes associated with this intervention is poor (80). The procedure 
itself also causes additional trauma in a patient with depleted physiologic reserves and it 
requires that the patient can survive transportation to a facility with the appropriate capability.  
 
2.5 MECHANICAL HEMOSTATIC ADJUNCTS 
 
2.5.1 Extremity tourniquets 
The most important cause of reduced mortality after extremity hemorrhage 
in military medicine, is the established use of tourniquets. Controversies 
exists regarding the use of this ancient device to control extremity 
hemorrhage. However, the emphasis of its use in the battlefield have 
increased the survival of extremity injuries to over 90%. Possible 
complications include unnecessary amputations resulting from limb 
ischemia, organ damage including renal failure, clots, myonecrosis and 
nerve palsies. In summary, Kragh et al. have, in a series of reports, based on 
extensive military data, shown evidence supporting the efficacy and safety 
of appropriately used tourniquets to control lethal hemorrhage from the extremities (81-83). 
Importantly, survival was strongly associated with application before the onset of shock (83).  
Generalization to civilian care is not uncomplicated. Differences in patient populations, 
including higher proportions of elderly and paediatric patients, and significantly higher ratios 
of co-morbidities exists. Data regarding use of tourniquets in the civilian care is limited and 
recommendations for use are vaguer than in the military (84). Furthermore, military indicated 
use of a tourniquet may result from tactical reasons not applicable to civilian prehospital care. 
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However, fear of complications must be rational and with the judgemental and proper use it 
may be an increasingly utilized intervention also in the civilian environment (85-87). 
 
2.5.2 Truncal tourniquets 
The widespread use of extremity tourniquets and their effectiveness in military operations 
resulted in a shift of focus in military medical research, pragmatically addressing the abdomen, 
pelvic- and junctional regions as the now most common sources of preventable death from 
exsanguination. New devices that could close off the arterial inflow to these regions were 
proposed for evaluation.  
Compression of the abdominal aorta to decrease blood flow to distal bleeding sites is a medical 
procedure that has been used in both trauma and post-partum (PPH) hemorrhage for decades. 
Manual pressure over the distal abdominal aorta or proximal inguinal artery can be effective to 
stop distal bleeding. However (beside the case of a recently pregnant woman with diastasis of 
the abdominal rectus muscles), the caregiver may need to apply around 588.4 N of pressure, 
comparable to a body weight of 92 kg during short-term periods or 115 kg to maintain occlusion 
during longer transports (24, 88).  
The first published report of a truncal aortic occlusive device, an 
abdominal tourniquet, was published in 1964 by Edwards et al (89) 
describing the idea of regional perfusion of the lower extremities with 
therapeutic agents (chemotherapy and antibiotics) in doses that would have 
been deleterious if administered systemically. The authors summarize the 
procedure as “…The major problems encountered were technical 
difficulties in an epidural catheter [which was used for injection of a saline 
bolus to compress the epidural venous plexus that risked shunting of blood 
between the regionally perfused body parts], circulatory disruption when 
the tourniquet was applied and (especially) removed, blood loss and a 
critically ill patient in the postoperative period”. Other external devices designed to 
mechanically occlude large arteries go back in history to at least around 1830. One example is 
the Esmarch´s aortic tourniquet that, in the hands of a surgeon with comprehensive anatomical 
knowledge, was successfully used to control hemorrhage during surgery (90). In modern 
history (2004) another custom made abdominal aortic tourniquet was assessed as a first aid for 
PPH (91). The authors conclude the intervention as a “cost effective and easily applied 
manoeuvre that allows satisfactory management of PPH without maternal mortality or 
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morbidity. It is of value in developing countries”. Given the historical background, and the 
physiologic prudence of hemorrhage control by external compression of truncal arteries, a 
modern, well-designed truncal tourniquet was re-introduced in combat casualty care around 
2012.   
The Abdominal Aortic and Junctional Tourniquet (AAJT; Compression Works, Alabama, US) 
is a device designed to occlude blood flow through the infra renal aorta by pneumatic 
compression of the abdomen. It has been shown to effectively reduce bilateral iliac blood flow 
in human volunteers and to be hemodynamically tolerable for two hours in porcine models (92-
94). A major advantage of the AAJT is that it is easy to use, and thus may be managed by non-
medical professionals. In addition to hemorrhage control, the increased systemic vascular 
resistance (SVR) from aortic occlusion can provide a resuscitative effect and lower the need 
for resuscitation fluids (95). A single, anonymous case report from 2013 described the first use 
of the AAJT in a successful resuscitation of a battlefield casualty (96). In addition, two case 
reports of clinical use with focal application to injuries in the axilla and groin has been 
published (97, 98).  
Figure 8. The Abdominal Aortic and Junctional Tourniquet® 
 
The AAJT is applied over the umbilicus and secured with a waist-strap before inflation of the wedge shaped, 
pneumatic bladder which compresses the abdominal aorta between underlying tissues and the vertebral column. 
Photo: Personal stock 
A limitation for establishing the AAJT into clinical practice is insufficient physiological data 
regarding the adverse effects, particularly in case of prolonged application and the evidence of 
any specific organ damage related to the AAJT had not been addressed prior to study I in this 
thesis. Assumed complications of the device include severe ischemic injuries to abdominal 
organs and lower extremities and life-threatening metabolic derangement after removal (93, 
99).  The current abdominal application time-limit of 60 minutes have not been associated with 
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any long-term detrimental effects in animal studies, however, removal after two hours may 
cause reversible metabolic and respiratory complications in pigs (93). Further knowledge of 
complications with AAJT application and subsequent removal can increase patient safety and 
use of the device. These aspects were addressed in study I in this thesis.  
 
2.5.3 Resuscitative Endovascular Balloon Occlusion of the Aorta (REBOA) 
Figure 9. The ER-REBOA™ catheter.  
 
A commercially available device with the desired traits of a REBOA catheter. It contains a curved tip for 
atraumatic insertion through the vessels. The compliant balloon is distally- and proximally demarked by 
radiopaque bands.  A double-lumen catheter (one communicating with the balloon and one for proximal arterial 
pressure monitoring) with length markers. From Alamy stock photo. Reproduced with permission.  
 
History and objectives with REBOA 
Resuscitative endovascular balloon occlusion of the aorta (REBOA) was first described 1954 
during the Korean war (100) and the first report of an animal model (canine) for studies on the 
feasibility of intra-aortic balloon occlusion in massive traumatic hemorrhage was published in 
1953 (101). In this technique, a catheter based inflatable balloon is inserted via an introducer 
(usually 7F size) in the common femoral artery and positioned in the infra-renal abdominal 







Figure 9. Aortic zones for REBOA placement.  
 
Zone I (thoracic): The left subclavian artery to the celiac trunk (aorta descendens); Zone III (infra-renal): Below 
the most distal renal artery to the bifurcation. The para-visceral aorta in zone II is considered as a “no-go” zone 
for REBOA due to decreased possibility to control hemorrhage and risk of abdominal organ injuries. From Heindl 
S, Et al. Partial Versus Complete Resuscitative Endovascular Balloon Occlusion of the Aorta in Exsanguinating 
Trauma Patients With Non-Compressible Torso Hemorrhage. Cureus. 2020;12(7): e8999. (103). Reproduced with 
permission.  
When the balloon is inflated, the distal aortic blood flow is occluded. The objective with 
REBOA is similar to the resuscitative thoracotomy (RT) manoeuvre with temporal decrease in 
arterial inflow to the injury site and augmentation of cerebral and coronary perfusion by 
increased cardiac afterload (104). After the first report by Hughes in 1954, publications 
regarding REBOA were sparse for decades. In recent years, with developments in endovascular 
medical procedures and technical advancements in catheter-based interventions, REBOA have 
been reintroduced as an adjunct for hemorrhage control (102). In response to the increase of 
vascular injuries, during the conflicts in Iraq and Afghanistan, the US military reconsidered 
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REBOA as an alternative for casualties with potentially lethal NCH (105). Indications and 
recommendations for clinical use in civilian trauma has later been published in the US (106).  
Figure 10. A sample emergency-room REBOA algorithm. 
 
Example of an algorithm for consideration of REBOA in trauma patients. Modified from Stannard et al(102).  
The implementation of REBOA in civilian trauma care has not yet been shown to improve long 
term mortality rates, however, superior outcomes compared to RT have been reported (107, 
108). Translational research also provided evidence of less metabolic insults with REBOA over 
RT (80). The principal expected physiological response after inflation of the balloon is a 
prompt increase in proximal SBP of around 50-70 mm Hg (109-111). The result of the 
increased cardiac afterload from aortic occlusion is restoration of organ perfusion proximal to 
the balloon (110). However, the high resistance to cardiac outflow is also associated with an 
increased myocardial workload, and thus, VO2 (112). The profound cardiac burden associated 
with zone I REBOA has further been shown to risk a type-2 myocardial injury after prolonged 
intervention times (> 2 h) (113). Similar to the AAJT, distal ischemia and impending 
reperfusion injury with severe systemic changes (hypotension, acidosis, hyperkalemia and 
hyperlactatemia) poses the great challenges with REBOA (114, 115). Current 
recommendations state a 30 minute (for zone I) and 60 minute (for zone III) maximum 
occlusion time based on both human and translational research (115). Acute kidney injury 
Pelvic fracture on  
x-ray? 
Zone III REBOA 
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not responding to standard resuscitation? 
Zone I REBOA with 
immediate laparotomy 
Penetrating thoracic injury or blunt 
thoracic trauma with suspected or obvious 
hemorrhage? 
Intra-abdominal hemorrhage as detected by 










(AKI) has also been shown as a common and potentially deleterious complication associated 
with REBOA (111). 
The demonstrated effectiveness of REBOA, to achieve temporary hemorrhage control, has also 
led to propagations for its use prehospital  (116) and a few reports have been published showing 
its potential (117, 118). The use of REBOA in prehospital locations raises new questions 
regarding its appropriate use. The category of possible providers may differ significantly from 
civilian to military trauma systems. Furthermore, the anaesthetic management of the patient 
without standard intra-operative (112) monitoring possibilities is challenging (119). Technical 
improvements and training in REBOA is likely to increase safety. However, several critical 
moments, which are summarized in Figure 11, need to be recognised by the care-giver 
performing REBOA (38).  
Figure 11. Steps for REBOA placement with associated potential complications.  
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Increasing evidence suggests important differences in hemodynamic effects between thoracic 
and infrarenal REBOA. As the primary objectives of REBOA are hemorrhage control and 
proximal hemodynamic support this may have significant implications for the further 
management of patients eligible for REBOA. It seems likely that a zone III aortic occlusion 
(AO) provides lesser hemodynamic support than a zone I occlusion. Examination of human 
patients with REBOA in zone I or III has shown that the effects on blood pressure and heart 
rate differ. The mean increase in SBP after zone I REBOA were 94% (64 to 124 mm Hg) versus 
31% (75 to 98 mm Hg) after zone III REBOA (120). The mean decrease in SBP after deflation 
however, did not differ (14 mm Hg, zone I versus 12 mm Hg in zone III respectively). Another 
study confirmed these findings after an analysis of patients included in the prospective 
observational AORTA registry between 2013-2017 (121). In that study the mean increase in 
SBP was significantly associated with the aortic zone of occlusion with lesser improvements 
in hemodynamics after infra renal REBOA. Animal studies have further questioned the use of 
zone III REBOA in hemodynamically unstable patients  (122).  
The similar indications for the AAJT and zone III REBOA prompted an investigation of 
physiological differences after resuscitation with the devices (123). In this animal study both 
devices were found to obtain 100% hemostasis and no difference in mortality was observed. 
The AAJT animals had higher MAP but also increased lactate levels after 1h intervention time. 
This indicates that the AAJT may be a more suitable option for hemorrhage control and 
hemodynamic resuscitation in the early phases of care. We addressed this question in study II 
were the physiological and metabolic effects were further compared in relation to fluid 
requirements and application time. Furthermore, as the logical step for patients resuscitated 
with the AAJT, we examined the feasibility of transition between the interventions in study III. 
This manoeuvre is likely necessary to obtain hemorrhage control, avoid hemodynamic collapse 
and provide ability to perform surgery on the patient.   
Aspects of prehospital REBOA  
In a retrospective analysis of combat casualties (n=244), 19%  were found to may have 
benefited from prehospital REBOA intervention (124). These patients had remaining 
circulation during evacuation but died en route or after hospital admission with a median time 
of 75 min from injury to death. The distribution of deaths was 46% at the scene, 37% during 
transport and 17% in-hospital. The median prehospital time for the patients transferred to a 
hospital was 61 minutes. A panel of international civilian and military experts on the field of 
NCH reached consensus on the military prehospital environment as a potential location for 
REBOA intervention, but not in civilian prehospital care (125). However, successful REBOA 
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has been performed (as described in a case report) in the civilian prehospital emergency care 
by the London Air Ambulance (116). In the military operations, the first use of “prehospital” 
REBOA on 4 patients was reported by Manley et al. in 2017 (126). These patients were treated 
by a forward surgical team within 10 minutes’ transportation from the point of injury but 2 
hours from the next level of care. None of the provider physicians had previous specialty 
training in endovascular techniques, but all had undergone a standardized training course in 
REBOA. Furthermore, these care-givers were originally assigned to a level I trauma centre and 
thus highly experienced in management of trauma patients. This case series also underlined the 
usefulness of REBOA to facilitate induction of anaesthesia in hemodynamically unstable 
patients. All patients survived to be transported with stable physiology to the next level of care 
and no procedural complications were reported.  
The lack of diagnostic and monitoring equipment in austere environments, for example x-ray, 
warrants different approaches to the question of when to perform REBOA in these 
environments. Another case-series report provided one example of a pragmatic algorithm for 
REBOA indications during these circumstances. Here, the mechanism of injury (high energy 
trauma), injury type (sub-diaphragmatic bleeding as confirmed by ultrasound), and vital signs 
(SBP < 90 mm Hg) were used to guide the initiation of  zone I REBOA (127). The crucial 
aspect of balloon positioning without imaging technology has been specifically addressed by 
correlation of skeletal landmarks and vascular anatomy as investigated by computer- 
tomography (128). For average height humans, the investigators suggest a fixed length of 48 
cm for zone I insertion and 28 cm for zone III. Importantly, and in parallel with the length of 
the aortic zones, I: 21.6 cm; III: 8.7 cm (Fig. 9), the error of these fixed insertion lengths was 
0.4% and 33.3% in blind zone I versus zone III placement.  
Finally, deflation of the balloon may be the most challenging step in REBOA provided that the 
patient has survived definitive hemorrhage control surgery. Hemodynamic instability from the 
reduction in afterload and ischemia induced vasoplegia and capillary leakage often requires 
vaso-active pharmacological treatment.  The profound metabolic derangements associated with 
ischemia reperfusion has been shown to develop for up to 90 minutes (animal data from 45-, 
60 and 90 minute zone I occlusion times) after balloon deflation (114). Severe electrolyte 
derangements (hyperkalemia and hypocalcaemia), hypoglycaemia and acidosis must be 
expected and treated to prevent lethal arrhythmias and organ failure. Therefore, balloon 
deflation should only be performed under vigilant monitoring with capability to treat these 




Aortic occlusion time and ischemic injury 
Much research interest has been put into mitigation of the adverse effects of REBOA in recent 
years. Ischemia reperfusion injury (IRI) is the complicated process causing further damage to 
ischemic tissues after return of blood circulation and oxygenation. Fundamentally, the grade of 
severity of IRI depends on the organ ischemic insult and thus, with REBOA, total occlusion 
time (129). Tissues are differently sensitive to hypoxia. For example, skeletal muscle can 
tolerate much longer ischemic time than the brain or the kidneys. Translational research has 
shown an undisputed correlation between occlusion times and degree of acidosis and pro-
inflammatory cytokine levels (115, 130). In other clinical backgrounds such as transplantation 
of organs and coronary interventions, specific pharmacological treatment of IRI exists. 
Mitigation of inflammatory pathways, formation of free oxygen radicals and nitric oxide 
constitutes important targets for these drugs (131-133).   
The degree of ischemic injury developing during REBOA may also be altered with modified 
management strategies of complete aortic occlusion. Two possible strategies, that both includes 
permissive distal aortic flow, have been proposed. In partial REBOA (pREBOA) incomplete 
AO is used balancing proximal hemodynamics and risk for further blood loss with the aim of 
prolonging the tolerable ischemic time. Several reports have shown promising results with this 
technique and with future development of more advanced catheters, variable and individually 
titrated AO is thought to form a new standard for REBOA management (134-137). Another 
technique used for reducing the total ischemic time to distal organs is intermittent REBOA 
(iREBOA), where restoration of aortic blood flow in a time- or blood pressure controlled 
manner is allowed. No human data exists supporting the use of iREBOA. However, a few 
animal studies has shown that after an initial inflation time of 15 minutes, continuing with 
iREBOA was associated with decreased levels of lactate and whole blood requirements to 
maintain MAP and decreased acidosis compared to continuous and complete AO (138, 139). 
These studies also suggested a more favourable metabolic and hemodynamic profile, using 
blood pressure limits to guide re-inflation of the balloon over a strict time-based protocol.  
In austere environments, the use of REBOA with permissive distal flow strategies may be 
challenging. Titration of pREBOA is limited by the monitoring capabilities in these 
environments. Deflation of the balloon (total balloon volume) has also been shown to not 
correlate with the return of blood flow in the distal aorta. Rather, a “steep inflection point” 
occurs at an unpredictable degree of deflation that results in an abrupt decrease in proximal 
arterial pressure (140). This is in part understood as the combined effects of intravascular 
volume, aortic vessel-wall compliance and mechanistic properties of the balloon. Blood-flow 
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dynamics during REBOA is complex and poorly understood. The postulation that organ blood 
flow is principally following the aortic flow rate has been shown to be wrong. Instead, REBOA 
was shown to not only affect aortic branch vessel flow during intervention, but also up to 45 
minutes after balloon deflation (141). In that study, the worst recovery of blood flow was 
observed in the renal arteries. This phenomenon is at least in part thought to result from IRI.  
Lastly, AO does not completely stop distal blood flow due to collateral circulation to a differing 
extent. Remaining blood flow both at the site of vascular injury and distal to the introducer 
sheath have been shown in human patients undergoing REBOA (142). In study IV, we 
therefore aimed to study the effects of an iREBOA protocol on IRI and organ injury of the heart 
and kidneys in correlation to overall hemodynamic variables and renal artery blood flow 
(RBF).   
 
2.6 EXPERIMENTAL ANIMAL MODELS IN TRAUMA RESEARCH 
Preclinical animal research, in the setting of trauma and hemorrhage shock, constitutes an 
irreplaceable source of evidence for development of new interventions and studies on complex 
physiological courses such as coagulation and shock (143). However, a general lack of 
uniformity regarding laboratory animals (144) and experimental designs hampers the 
translation of experimental results into clinical praxis (145). A useful animal model for trauma 
research should include the combination of early mechanical and subsequent innate physiologic 
reactions associated with tissue trauma, hypovolemia, regional or systemic hypoxia, 
inflammation and immune reactions to organ damage and shock (146). Swine is the most 
commonly used animal in preclinical, traumatic hemorrhage research (146). In terms of a, non-
primate, large animal model the pig is reasonably similar to humans in vascular and visceral 
dimensions (147), physiological responses to tissue damage (148), cardiovascular dynamics 
and pharmacological therapy (149). Furthermore, pigs are cost-effective. Induction of 
hemorrhage shock is principally performed by removing blood from the animal through a 
controlled or uncontrolled extravasation (150).  Furthermore, the simulated hemodynamic 
effects and depth of shock can be achieved by either a fixed targeted blood pressure, pressure 
controlled, (149, 151) or a fixed hemorrhage volume, volume controlled mode, (152-154). The 
infliction of tissue trauma to a hemorrhage research model can be performed by a single- or 
multiple insults to the organ of interest based on the aims in the specific study. In conjunction 
with human trauma populations, the large heterogeneity of clinical scenarios should be 
addressed specifically. Commonly used trauma models include blunt or penetrating injuries to 
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the head, chest, abdomen or extremity bone-fractures in combination with soft tissue damage 
(143). A systemic inflammatory response, mimicking a septic-reaction, can further be induced 
by injection of endotoxins (155, 156).  
Coagulation effectivity and levels of parameters used for its evaluation differ between species 
(157, 158). Swine are known to be hypercoagulable compared to humans in response to 
traumatic hemorrhage (159). Nonetheless, porcine models are the most commonly used in TIC 
research due to the otherwise similar organ and hemodynamic physiology. Numerous studies 
have been performed trying to create a robust porcine model for TIC research. However, the 
large majority are disadvantaged by having only established coagulopathy by means of the 
traditional homeostatic derangement, induced by hemodilution and hypothermia in 
combination with hemorrhage shock. For ATC to ensue after trauma in humans, severe injury 
(injury severity score; ISS of 25 or greater) along with hemorrhage shock corresponding to a 
base deficit of 6 mmol/L is required (43). We therefore, in study V, aimed to establish a 
reproducible porcine model for future TIC research fulfilling the requirements of mechanistic 
and metabolic preconditions for TIC in humans, along with investigating a ROTEM profile for 
its detection in pigs.         
In summary, no single generic animal model can address the large variety of 
pathophysiological courses arising from trauma and the weaknesses and strengths of the 













3 RESEARCH AIMS 
 
The overall aim of this thesis was to provide physiological data on novel, mechanical 
hemostatic adjuncts to facilitate their implementation into clinical practice and to contribute to 
the important research area of trauma-induced coagulopathy. 
The specific aims of the contributing studies in this thesis were as follows: 
 
I. To investigate the physiologic consequences of an abdominal aortic tourniquet, in 
relation to application times.  
II. To compare crystalloid fluid requirements during resuscitation with an abdominal 
aortic tourniquet versus infrarenal Resuscitative Endovascular Balloon Occlusion 
of the Aorta.  
III. To investigate the feasibility and physiologic effects of transition from an 
abdominal aortic tourniquet to infra-renal Resuscitative Endovascular Balloon 
Occlusion of the Aorta.  
IV. To study the hemodynamic effects and organ function of the heart and kidney of 
recurrent reperfusion intervals during 60-minute thoracic Resuscitative 
Endovascular Balloon Occlusion of the Aorta.  
V. To investigate a porcine research model for studies in acute traumatic coagulopathy 




4 MATERIALS AND METHODS 
 
4.1 ETHICAL PERMITS 
The studies in the present thesis was approved and conducted in accordance with the Swedish 
regional ethics approval board for animal research in Stockholm. Study I: ID S3-15, Study II: 
ID S3-15, Study III: ID S3-15, Study IV: ID S3-15 and 1470, Study V: ID S3-15 and 1470.  
 
4.2 LABORATORY ANIMALS 
Sexually immature female (n=3) and castrated male (n=57), Yorkshire-Landrace cross pigs 
(Sus Scrofa) of 6 months old were utilized in the experiments. Pigs were obtained from an 
accredited breeder which ensured healthy and physiologically uniform animals. Mean body 
weight of the animals were in study I: 60 kg, study II:  60 kg, study III: 57 kg, study IV: 60 kg 
and study V: 63 kg. These animals were utilized based on their human similarity in torso and 
abdominal organ dimensions. The animals were housed at least three days prior to the 
experiments in an accredited laboratory animal facility with an ambient room temperature at 
21-22°C and 12-hour day/night cycles. Prior to the experiments animals were fasted for 12 
hours with free access to tap water.  No animal was excluded due to any abnormal behavior, 
obvious signs of sickness or injury or outlying base-line data. Randomization to study groups 
was conducted in all studies after completion of surgical preparation by the sealed envelope 
method. 
 
4.3 ANESTHESIA AND EUTHANASIA 
Animals were sedated with an intramuscular injection of 150 mg tiletamine/zolazepam (Zoletil 
100 Vet) and 6 mg medetomidine (Domitor) and transported sleeping to the operating room. 
After recording of weight the animals were placed supine on a standard operating table and 
pre-oxygenated for three min with 100% O2. Non-invasive blood pressure was measured in the 
hind leg and a tail probe was used for pulse-oximetry monitoring. General anaesthesia was 
induced through an auricular vein with pentobarbital, 6 mg/kg (Pentobarbitalnatrium vet., 60 
mg/mL); atropine, 0.02 mg/kg (Atropin Mylan, 0.5 mg/mL); and fentanyl, 2.5 µg/kg (Fentanyl 
B. Braun, 50 µg/mL) and perioperatively maintained with a continuous i.v. infusion of 
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ketamine 25 mg/kg (Ketaminol vet. 100 mg/mL); midazolam 0.0485 mg/kg (Midazolam 
Hameln, 1 mg/mL) and fentanyl 3.5 µg/kg (Fentanyl B. Braun, 50 µg/mL) per hour. A standard 
size 8, cuffed endotracheal tube was inserted through a midline neck incision (study I-II) or 
orally, using a custom-made Miller-type, laryngoscope (study III-V). The animals were 
mechanically ventilated using a Hamilton C2 ventilator (Hamilton Medical, Geneva, 
Switzerland) to maintain a PaCO2 between 4.7 -5.5 kPa. Standard ventilator settings were: 
inspiratory oxygen fraction (FiO2), 21%; peak inspiratory pressure, 16-24 cm H2O; peak 
expiratory end pressure, 4-10 cm H2O and respiratory rate, 16-24 per minute. During 
preparation an infusion of 500 mL Ringer´s Acetate (RA) was administered to adjust for base-
line variances in fluid balance. To compensate for insensible losses during experiments, an 
infusion of 3 mL/kg per hour of Ringer´s Acetate was administered after induction of 
hemorrhage shock. At completion of the experiments, animals were euthanized with 35-70 ml 
pentobarbital sodium (Alfatal vet. 100 mg/ml). Criteria of death was etCO2 < 2 kPa, MAP < 
20 mm Hg and asystole on EKG. 
 
4.4 SURGICAL PREPARATION AND INSTRUMENTATION 
A 7.5F Swan-Ganz pulmonary artery catheter (Edward Lifescience, Irvine, CA) was introduced 
through the surgically exposed right external jugular vein and used for core temperature, central 
venous pressure (CVP), cardiac output (CO) and mixed venous oxygen saturation (SvO2). In 
study I-II, the left carotid artery was exposed via the midline neck incision and used for blood 
pressure (BP) monitoring, blood sampling and blood withdrawal. In study III-V, a standard 
arterial catheter was placed in either brachial artery under ultrasound guidance (SonoTouch 20, 
Chison Medical Imaging CO., China) and used for BP monitoring and blood sampling. In study 
II-V, either femoral artery was percutaneously cannulated with a (II-IV) 7F introducer sheath 
(Merit Medical Systems Inc., UT) or a (V) 13.5F, 15 cm silicone dialysis catheter (Medical 
Components Inc., Harleysville, PA) and used for blood withdrawal and REBOA insertion. A 
suprapubic urine catheter and three intracutaneous EKG electrodes were placed in all animals. 
In study III-IV, the contralateral femoral artery was surgically exposed for later transection. In 
study IV the left renal artery and vein was surgically exposed via laparotomy. A perivascular 
ultrasound flow probe (Transonic Systems Inc., NY, USA) was placed on the renal artery and 
a standard 1.5 mm i.v. catheter was inserted in the renal vein. The abdomen was temporarily 




4.5 INDUCTION OF HEMORRHAGE SHOCK 
Total blood volume (TBV) was calculated by (I-IV) 67 mL/kg and (V) 65 mL/kg. Hemorrhage 
was completed (study I-II, V) or initiated (study IV) by blood withdrawal through the carotid 
(I-II) or femoral (IV-V) artery catheter using a peristaltic pump (Masterflex L/S, Cole Parmer) 
until the target blood loss or collection to citrated bags for later autologous transfusion was 
achieved. In study III and IV a free bleeding of the total or remaining blood loss was used via 
transection of either femoral artery. Hemorrhage volume was measured by weight of the 
collection container, citrate bags and gauzes. Citrate bags used for autologous transfusion were 
stored at 38°C. No splenectomy was performed in the experiments. 
Study I-II: A two-phased, pressure controlled bleeding was used to induce a class II 
hemorrhage shock. Initially, 12.5% of TBV was drawn for 7 minutes. After a stabilization 
period of 10-15 min the bleeding was continued at halved rate to a MAP < 40 mm Hg.  
Study III: A free bleeding of 40% of estimated TBV was used via transection of the femoral 
artery. Extravasated blood was collected by suction to a container and collected in gauzes. The 
bleeding was periodically paused by manual pressure while total blood loss was calculated. 
After completion of hemorrhage the bleeding was paused and the animals left for 15 min to 
induce hemorrhage shock.  
 
Figure 12. A detail picture of the left femoral sheath with a: vein; b: artery and c: nerve. Notably, this exposure 
of the injury caused an uncontrolled external hemorrhage. The rate of blood-loss may vary considerable with 
remaining overlying tissue and formation of a hematoma exerting counter-pressure to the vessel.   
Study IV: A hybrid hemorrhage protocol of a 40 % estimated TBV was utilized to produce a 
class IV hemorrhage with severe hypotension. Hemorrhage was initiated by blood withdrawal 
to citrate bags (2 x 450 mL at 100 mL/min) followed by transection of the femoral artery. The 
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free bleeding was periodically paused by manual pressure of the femoral artery while total 
blood loss was calculated. When the targeted hemorrhage volume was achieved, the femoral 
artery was temporarily clamped during a period of 15 min to induce shock. The femoral artery 
was left unclamped during REBOA in order to investigate occurrence of rebleeding during the 
balloon deflation intervals. The hemorrhage protocol was found to be 100 % lethal without 
resuscitation in pilot studies. At 60 min, the transected femoral artery was clamped using a 
standard hemostatic forceps. 
Study V: Animals were subjected to a controlled hemorrhage; in positive controls of a 60% of 
TBV and in the groups pulmonary contusion and combined hemorrhage/polytrauma of a 25% 
of TBV respectively. 
 
4.6 TRAUMA MODALITIES (V) 
 
4.6.1 Pulmonary contusion 
The animals were subjected to pulmonary contusion by blunt trauma using a 59 g, 65 (diameter) 
x 55 mm polyethylene projectile with a mean velocity of 82.3 m/s from a firing distance of 3.3 
m. The projectile was fired using a custom made, compressed air gun, producing a 300-joule 
energy burst to the thorax at a fixed point (5 cm caudally and 2 cm ventral to the tip of the right 
scapula, 22-24 cm dorsally to the xiphoid process with the right front leg maximally abducted). 
Pulmonary contusion was confirmed by B lines and C lines by chest ultrasound and 
haemoptysis in the endotracheal tube. Additionally, post mortem calculations of lung injury 
volume and skin lesion was conducted for comparison of consistency. 
 
4.6.2 Blast polytrauma 
The animals were subjected to separate blast injuries at two sites. First, a blast injury to the 
groin was performed were the point of impact was above the midlevel of the femur. Second, a 
blast injury to the abdomen was performed with the point of impact one cm medially of the rib 
cage at level I6-I7 dx corresponding to a level above the liver. Swedish military grade plastic 
explosive (M/46) was used for the blast injuries. M/46 consists of 86% penthyl 
(pentaerytritoltetranitrat, C(CH2ONO2)4) and 14% mineral oil and has a detonation speed of 
8400 m/s. One g M/46 was taped to a non-electric initiation system (2 g capsule and 9 meter 
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of cord snapline SL-0), connected to a Nonel Dynostart ignition box (Dyno Nobel). The 
explosive charge was taped to the skin and covered by ceramic plates from a military grade 
body armour, and blankets. The animals were covered with flexible freezer packs to generate 
hypothermia, and the ventilator was adjusted for hypoventilation by decreasing the respiratory 
rate to 5-10 per min and decreasing pressure support, so that pCO2 would increase to >10 kPa 
within the 120 min observation period to establish respiratory acidosis. Lipo-polysaccharide 





After induction of hemorrhage shock the AAJT was tightened around the abdomen and fully 
inflated (300 mm Hg). Total occlusion of the aortic blood flow was verified by loss of pulse-
wave and non-invasive blood pressure distal to the device. Application times of the AAJT did 
not succeed one minute in all animals. The AAJT was fully deflated at 240 min (I-II) or 60 min 
(III) respectively, with no attempt to a stepwise reperfusion with the purpose of maximizing 




Study II: The REBOA balloon catheter (6F, 15mm diameter/50 cm shaft, REBOA Medical, 
Båstad, Norway) was inserted to the infra-renal (zone III) aorta via the prepositioned 
introducer, to a distance mark based on anatomical landmarks after completion of hemorrhage. 
The catheter-shaft was firmly fixed to the introducer with surgical tape to avoid balloon 
migration. The balloon was inflated with 8 mL normal saline (NS, NaCl, 0.9%) and left for 240 
min. A zone III balloon position was confirmed in post mortem laparotomy. The balloons were 
promptly deflated after 240 min and left in situ for the remainder of the experiments.  
Study III: After 30 minutes AAJT intervention a transition to zone III REBOA was performed 
in 6 animals. In these animals the REBOA catheter was advanced through the introducer until 
a resistance was felt corresponding to the AAJT pressure on the aorta. At that time, the AAJT 
was deflated simultaneously with partial inflation (4-6 mL, NS) of the REBOA balloon. The 
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REBOA catheter was carefully retracted until a distinct stop representing the level of aortic 
bifurcation. The balloon was re-advanced 2-3 cm to avoid iliac positioning and further inflated 
to a total of 8 mL NS for 30 min. After the 30 min REBOA intervention, the balloons were 
promptly deflated and left in situ for the remainder of the experiments. 
Study IV: The REBOA catheter was introduced to a supra-celiac position based on topical 
measurement in a standardized procedure, and left in position after completion of hemorrhage. 
After post-hemorrhage data sampling, the balloon was inflated (8 mL, NS) under hemodynamic 
monitoring. Total aortic occlusion was verified by a combination of steep inflections in 
proximal BP, hemostasis of the free bleeding and loss of distal BP and pulse-oximetry.  In this 
study one group (n = 6) was subjected to 60 min continuous full REBOA (cREBOA) and one 
group (n = 6) underwent a full balloon deflation of 180 s every 10 min for 60 min (5 deflations). 
The balloons were deflated promptly (typically 30 s) to ensure a uniform physiological 
response in the animals. During the intermittent reperfusions the balloon was re-inflated (rescue 
occlusion) if SBP decreased < 80 mm Hg. 
 
4.7.3 Fluid Resuscitation 
The intravenous fluid resuscitation consisted of RA and/or autologous whole blood. We used 
a protocol for crystalloid fluid infusion in accordance with current TCCC battlefield 
resuscitation guidelines (160).  
Study I-II: Bolus infusions of 250 mL RA as needed, was given if MAP decreased < 60 mm 
Hg in all study groups. At the end of the 60 and 240 min interventions times autologous whole 
blood (450 mL) was transfused and additional RA until MAP approximated baseline. Rapid 
infusion of 2000 mL RA was continued throughout the reperfusion phase.  
Study III: After inflation of the AAJT rapid infusion of RA was started until MAP reached ≥ 
60 mm Hg, after which no further additional resuscitation fluids were administered.  
Study IV: Simultaneously with inflation of the REBOA one bag of whole blood (450 mL) was 
administered. The animals were transfused with one additional bag of whole blood (450 mL) 
immediately prior to final deflation of the balloon and rapid infusion of 2000 mL RA were 
administered during the critical care phase. No resuscitation fluids were administered during 
the induction of hemorrhage shock or REBOA intervention. 




4.7.4 Vasoactive support 
Intravenous infusion of norepinephrine at 0.1µg/kg/min was used in the experiments. Infusion 
times were automatically recorded using a syringe infusion pump (B Braun, Hessen, Germany) 
and data were collected post-hoc. In study I-II and IV, infusion was started during the critical 
care phase after AAJT/REBOA deflation when MAP decreased < 60 mm Hg and stopped at 
MAP > 90 mm Hg.  In study V, infusion was started if MAP decreased < 25 mm Hg during 




4.8.1 Computer tomography (I) 
Two animals from each AAJT group in study I underwent a standardized, contrast enhanced, 
CT scan of the thorax and abdomen before, and after 45 and 225 min AAJT application 
respectively. Image diagnostics were performed by a specialist radiologist using a 
questionnaire and an overall interpretation. The analyses consisted of blood flow patterns in 
major abdominal vessels and organs, anatomical description of organ affection and urinary 
outflow.    
 
4.8.2 Microscopic diagnostics (I) 
Tissue samples were collected from the aorta (between the bifurcation and most distal renal 
artery) intestine, kidney, liver, heart and the adductor muscle on hind leg post mortem. The 
specimens were fixed in formalin and stained with haematoxylin and eosin, blinded and 
analysed by a clinical pathologist.  
 
4.8.3 Hemodynamics 
Hemodynamic variables (HR, SBP, MAP, CO, CVP and RBF) was continuously monitored. 
RBF were expressed as relative changes from baseline values to adjust for individual 
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differences. EKG was monitored continuously and recorded hourly or at appearance of 
noteworthy changes in morphology or rhythm.  
 
4.8.4 Blood chemistry 
Arterial and renal vein (study IV) blood was collected at baseline, and at every 10-15 min 
during the experiments. pH, base excess, lactate, potassium, haemoglobin (Hb), hematocrit 
(hct), PaO2, PO2 (renal vein), PCO2, PCO2 (renal vein), glucose, ionized calcium and oxygen saturation 
(SaO2, SO2(renal vein)) were analysed.  
 
4.8.5 Urine output 
Urine output was collected continuously via the suprapubic catheter to a container and 
registered every hour by means of a custom made electronic weight scale.   
 
4.8.6 Organ blood markers 
Samples for troponin I and myoglobin were collected at baseline and post intervention and 
critical care phases and analyses were performed by the Karolinska University Hospital 
laboratory, Department of Clinical Chemistry, accredited by Swedac, Sweden's national 
accreditation body. Samples for creatinine (8L24, IDMS traceable enzymatic reagent) were 
collected at baseline and post intervention and critical care phases and were analyzed on a 
BS380 instrument (Mindray, Shenzhen, China) using reagents from Abbott Laboratories, 
(Abbott Park, IL, US). The total coefficient of variation for the creatinine method was 1.5% at 
87 µmol/L. 
 
4.8.7 Common femoral artery dimensions (III) 
In study III, the diameter of the common femoral artery was measured in the animals not 
randomized to transition between interventions using a 7.5 MHz linear transducer (Sono Touch 
20; Chison Medical Imaging CO Ltd, China) at baseline, hemorrhage completion and after 30 
min AAJT application. The measurements were conducted perpendicular to the long axis 
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immediately distal to the inguinal crease corresponding to the site of REBOA catheter 
introducer.  
 
4.8.8 Coagulation tests (V) 
Tests for PT(INR) (photometry), aPTT (photometry), platelets (impedance and flow 
cytometry), fibrinogen (photometry), prothrombin (turbidimetry), aPC (enzymatic activity, 
photometry), D-dimer (turbidimetry) and ROTEM (INTEM, EXTEM, APTEM and FIBTEM) 
were performed by the Karolinska University Hospital laboratory, Department of Clinical 
Chemistry, accredited by Swedac, Sweden's national accreditation body. ROTEM was 
performed by the laboratory using a ROTEM Delta (Werfen), according to the manufacturer’s 
instructions, and quantified for clot formation time, alpha angle, clotting time and maximum 
lysis time. Enzyme-linked immunosorbent assays (ELISA) were performed to quantify tPA 
(Innovative Research, Inc. Catalog No. IPTPAKT, lot No. 915) and PAI-1 (Innovative 
Research, Inc.  cat. No. IPOPAIKT, lot No. 317), according to the manufacturer’s instructions. 
 
4.9 STATISTICAL ANALYSES AND CALCULATIONS 
Statistical analyses were made using GraphPad Prism version 7.0.3-8.4.3 (GraphPad Software 
Inc., La Jolla, Ca) for windows. A p < 0.05 was considered significant. The following 
calculations were used for hemodynamic parameters: Stroke volume (SV) = CO/HR; Systemic 
vascular resistance (SVR) = 80 x (MAP-CVP)/CO.  
I. For myoglobin, two-way analysis of variance with Sidak´s multiple comparisons 
test was used. For norepinephrine Student´s unpaired t test was used. For Ringer´s 
Acetate and hemorrhage, two-way analyses of variance with Tukey´s multiple 
comparisons test was used. The primary outcome was survival at AAJT release. 
Secondary outcomes were fluid requirements to maintain MAP and respiratory and 
hemodynamic variables associated with AAJT application. Error bars in figures 
represent SEM. 
 
II. Two-way ANOVA with Sidak’s multiple comparisons test was used for 
hemodynamic and metabolic parameters. Student’s unpaired t-test was used for 
norepinephrine. Two-way ANOVA with Tukey’s multiple comparisons test was 
used for iv fluids and hemorrhage volume. Primary outcome was cumulative 
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crystalloid fluid requirements to maintain MAP > 60 mm Hg. Secondary outcomes 
were hemodynamic and metabolic parameters. A power calculation for a 
continuous outcome superiority trial was performed and 12 animals were required 
to have an 80% chance of detecting a 2500 ml difference in the primary outcome 
(α = 0.05). Standard deviations were calculated from pilot studies. For five animals 
in the AAJT group, a secondary analysis of previously published data was 
performed (160) and one animal was added according to the power calculation. All 
data are expressed as the mean ± SD. 
 
III. A two-sample calculation was used for power analysis: (n ≥ (Zα/2 + Zβ)2 x 2 x 
Sp2/C2). Assuming an effect size of 20 mm Hg (least clinically significant 
difference) and an α = 0.05, a sample size of 6 animals/group were utilized to reach 
80 % power. Pooled standard deviation was calculated from previously published 
data and pilot studies. Comparisons of hemodynamic and metabolic variables 
between groups were performed using repeated measures, two-way ANOVA. 
Sidak´s multiple comparisons test was applied for post hoc corrections. For SBP 
and MAP variability an unpaired, two-tailed t-test was used. For body weight, 
hemorrhage volume and IV fluids independent t-tests were used. Vascular diameter 
changes were reported as simple means.  
Primary outcomes were arterial blood pressure variability and hypotension 
duration. Secondary outcomes of interest were cardiac output, systemic vascular 
resistance, pH, lactate, base excess, visible re-bleeding from the injury and common 
femoral artery lumen diameter. 
 
IV. Comparisons of hemodynamic variables, urine output and metabolic changes were 
performed using repeated measures, two-way ANOVA. Sidak´s multiple 
comparisons test was applied for post hoc corrections. For hemorrhage volume, 
nor-epinephrine infusion time, total ischemic time and organ specific blood markers 
unpaired t-tests were used. We assumed an effect size of 0,67 (difference in survival 
between groups with death occurring during intervention or reperfusion phases) 
based on published data and our groups pilot studies on the present iREBOA 
protocol. An a priori sample size calculation using a two-tailed t-test family with 
an α = 0.05, yielded a sample size of 12 animals to reach 80 % power (G*Power, 
version 3.1.9.4). Primary outcome of interest was mortality. Secondary outcomes 
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of interest were total ischemic time, renal blood flow (% of BL), urine output, 
hemodynamic- and metabolic changes. Error bars in figures represent SEM.  
 
V. For temporal data sets, a mixed effects model with the Geisser-Greenhouse 
correction was used, comparing all groups to negative controls. For hemorrhage, 
Ringer´s Acetate and all coagulation tests an unpaired t-test was used, comparing 
all groups to negative controls at the corresponding time (0 min, 20 min, 120 min). 
Statistical analyses of ROTEM were performed using the R project for statistical 
computing (the R foundation) v.3.4.2. ROTEM-data were first analysed using a 
multi-variate ANOVA and visualized using principal component analysis (PCA), 
followed by an analysis of individual variables with Kruskal-Wallis test using 
Mann-Whitney U-test with a Benjamini-Hochberg correction for post-hoc 
evaluation. p<0.05 was considered statistically significant. Heteroscedasticity in 
ROTEM was evaluated by Bartlett's test for unequal variance between groups. The 
ROTEM data for CT, CFT, and alpha were found to be significantly 
heteroscedastic, unlike the data for MCF and alpha. The study assessed TIC by 
multiple coagulation tests. For calculation of power of the study, PT(INR) was 
chosen for a post-hoc power analysis for continuous endpoint, two independent 
sample study, and resulted in 81.5% power (group 1, negative control at 120 
minutes: mean 1.00, SD 0.0707, group 2, hemodilution at 120 minutes: mean 1.35, 
SD 0.2646, alpha 0.05). Error bars represent SD. 
 
4.10 ETHICAL CONSIDERATIONS 
Trauma research is inherently afflicted by difficulties with the conduction of prospective and 
randomized human trials. Heterogeneities within clinical practice, demographics, predominant 
mechanisms of injury, collection of reliable data and the possibility and appropriateness to 
obtain informed consent are examples of limitations to this issue. Hence, there is a need for 
alternative strategies to conduct scientific research in order to improve the outcomes after major 
trauma.  Laboratory animal studies can replace human studies and provide valuable knowledge 
in different aspects of medical research. For example, pre-clinical trials of novel 
pharmacological therapies and experimental surgical procedures are commonly performed on 
animals. Within the present research project, the use of laboratory animals is fundamental. The 
main objective with our study series is to significantly contribute to the development and 
introduction of novel treatment strategies for lethal, noncompressible hemorrhage. In order to 
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study the efficacy and safety of these interventions, a reproducible model with sufficient 
anatomical and physiological similarities with humans are required. Therefore, pigs of 
approximately 60 kg weight are utilized in our experiments. The complexity of the physiologic 
courses associated with the interventions and the need to study their effects on live tissue 
necessitates the use of living animals.  
Our research group is actively and continuously working with the ethical aspects of the 
utilization of laboratory animals in our studies. All studies are approved and conducted in 
accordance with the legislation and board of animal research ethics. The experiments cannot 
be replaced by human experiments, computer animations or other methods. However, in order 
to refine and reduce the number of experiments within the project a series of actions are 
undertaken: 
 Maximize the ability to publish results by development of well-defined hypotheses and 
research questions for each experiment including statistical calculations (when 
possible) to generate the minimal sample sizes required to reach statistical power (based 
on previously collected or published data). 
 Maximize the utilization of each animal including post mortem training and 
collaboration with other groups.  
 Minimize model development and pilot experiments by utilization of previously 
published and standardized procedures as far as possible.  
 Utilization of highest proficiency and procedural skills to minimize losses due to poor 
practical conduction of experiments. 
 Active dialogue with veterinary to ensure pre-trial animal welfare and that every single 
procedure is explicitly stated, understood and approved by the board of animal research 
ethics.   
 Extensive and standardised collection of physiological parameters and experimental 
data for future needs (including baseline parameters, anaesthetic and pharmacological 
implications even if not relevant to the actual experiment).    
 Ensure high quality data by abort experiments or exclude data if animals show signs of 
abnormalities. 




   
A second important aspect of ethical consideration within the present research project entails 
the protection of human rights during increased vulnerability in combat and disaster 
environments and the conduct of research during these circumstances. A significant amount of 
publications based on data collected in conflict or disaster environments have been used in the 
literature review for the present research project. Research in combat and disaster environments 
is governed by the same fundamental principles as in civilian biomedical research. Possible 
ethical issues that arises from this includes the utilization of data collected from trauma victims, 
survivors and demised, without information or any given informed consent to participate in 
research projects. Additionally, the decisional capacity may be affected by cultural or language 
barriers. To ensure that no part of the present research project contains unethical or questionable 
material, all references are carefully vetted for methods of data collection and if possible ethical 
aspects stated by the authors. Finally, references including laboratory animal research is 
carefully analysed for the generalisability according to methods and results and ethical approval 


















5.1 INDUCTION OF HEMORRHAGE SHOCK 
The protocols resulted in reproducible 25 – 60% of total blood volume hemorrhage. The 
hemodynamic changes during hemorrhage was a reduction in arterial pressures ranging 
between 50-80%. During the 10-15 min stabilization period after hemorrhage completion, 
MAP increased 10-15 mm Hg as a response to compensatory mechanisms. Splenic auto 
transfusion is a known phenomenon in swine models of hemorrhage shock and splenectomy is 
commonly used to reduce this compensatory effect. However, this procedure inherently causes 
an additional trauma from the laparotomy and also risks confounding of the results due to 
occult, ongoing bleeding from the surgical procedure. Furthermore, splenectomy have been 
shown to be avoidable in swine hemorrhage models utilizing pressure based protocols (161). 
We therefore did not perform this procedure.   
In study III-IV, a free bleeding by transection of the femoral artery was utilized to simulate a 
realistic injury with a natural bleeding rate, and to allow for quantification of rebleeding during 
transition between aortic occlusion interventions and balloon deflation during REBOA. In 
study III, three animals died during the induction of hemorrhage shock. As compared to study 
IV, no previous controlled hemorrhage was conducted (in order to collect blood for later 
autologous transfusion) and it is likely that the increased rate of blood loss (average bleeding 
time 19 min) caused the circulatory collapse. One animal was included in study III after 
circulatory collapse with ventricular fibrillation following completion of hemorrhage, and 
return of spontaneous circulation within 30 seconds of chest compressions during inflation of 
the AAJT.   
In study V, mean hemorrhage per kg was 15.9 mL (range 13.2-16.8) in pulmonary contusion 
with hemorrhage, 39.3 mL (range 29.1-40.2) in positive controls and 16.0 mL (range 0-17.5) 








5.2.1 Survival  
The overall survival rate in the experiments were 93% (56/60 animals). In study III, 3 animals 
died during induction of hemorrhage shock and therefore mortality was related to the 
hemorrhage protocol and the experiments were reiterated. In study IV, one animal died in the 
cREBOA group after reperfusion. No statistically significant inferior outcomes in mortality 
were therefore shown with 240 compared to 60 min AAJT intervention or 60 min continuous 
zone I REBOA over intermittent reperfusion intervals. Hence, no survival benefit was proven 
according to the power calculations.  
 
5.2.2 Hemostasis 
Hemostasis was effective in all animals resuscitated with the AAJT and REBOA. CT 
examinations of blood flow in study I showed a total infrarenal occlusion of blood flow in the 
aorta and inferior vena cava and during intervention the pulse-oximetry and distal non-invasive 
blood pressure measurements were unmeasurable. The exposed and transected femoral artery 
in study III-IV showed no occurrence of quantifiable bleeding either during AAJT or REBOA 
intervention. Importantly, the transition procedure between AAJT and REBOA, even though 
conducted to minimize aortic overflow, and intermittent reperfusion intervals in study IV did 
not result in any rebleeding from the artery. These findings were unexpected and may not be 
applicable to humans. 
 
5.2.3 Hemodynamic effects 
In addition to hemostasis the aortic occlusion devices had a significant impact on the proximal 
arterial pressures. The principal mechanism for the improved blood pressures was a drastic 
increase in SVR and thereby cardiac afterload. This effect was observed to be greater in the 
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Figure 13. SVR was increased by the AAJT as compared to zone III REBOA (b) with associated increased systolic 
blood pressure (c) 40 min after application (*p<0.05).   
After AAJT application the aorta was occluded distal to the renal arteries, however, the 
significant compression of abdominal tissues cranially is likely to also have affected the 
abdominal circulation which impacted the SVR.  
 
Figure 14. CT scan of a 60 kg pig with inflated AAJT. Note the contrast filled aorta with seized flow below the 
device and the cranially forced abdominal organs with the high standing diaphragm.  
After zone I REBOA, the aortic pulse reflection is almost immediate and thus affects both 
cardiac output and coronary perfusion in diastole and systole. This is reflected by the steep, and 
supra physiologic increase in arterial pressure. Resuscitation with the AAJT and zone I 
REBOA caused a significantly increased heart rate to uphold cardiac output compared to zone 
III REBOA. A reduced venous cardiac return in combination with the substantial afterload 
reasons the tachycardia. Consequently, a compensation for contracted stroke volume to sustain 
cardiac output. Suggestively, stroke volume was also found to be significantly higher in the 
fluid resuscitation group (I) and during balloon deflations in the iREBOA animals (IV).  
The transition procedure in study III caused a significant decrease in arterial pressure (mean 25 
mm HG) during simultaneous deflation of the AAJT and inflation of the REBOA balloon. After 
transition to zone III REBOA these animals were hypotensive compared to the continuous 
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AAJT application. Our data suggested that the procedure can be safely performed with 
hemodynamic support such as a fluid bolus prior to deflation of the AAJT and vasopressor 

































Figure 15. MAP was significantly decreased following the transition procedure after 30 min intervention (dotted 
arrow) between AAJT and zone III REBOA (grey area).  
We showed that renal blood flow during intermittent REBOA was significantly higher during 
reperfusion intervals and after 60 min critical care. The renal aortic branch vessel flow during 
reperfusions corresponded to a decrease in proximal systolic blood pressure and increased 
blood flow distal to the balloon, however it was only restored to 27.5% of baseline values 
during the first 3 min reperfusion interval where after it decreased gradually to 13.5%. These 
results underline the complexity of the intrinsic mechanisms behind regulation of end organ 
blood flow. We did not perform measurements of blood flow in the carotid artery that could 
have revealed one possible explanation for the scarce return of RBF during balloon deflations. 
It is likely that preservence of blood flow to the brain in combination with endothelial hypoxia 
with vasoconstriction in the renal arteries have impacted the vaso-regulatory mechanisms and 
inferior blood flow in the renal arteries during full return of aortic blood flow. The interruption 
of worsening renal ischemia during iREBOA may therefore explain that the restoration of RBF 
after critical care reached 61% (iREBOA) compared to 39% (cREBOA). 
 
5.2.4 Fluid requirements 
In study I, we compared the crystalloid fluid requirements between animals resuscitated with 
the AAJT and a control group receiving crystalloids only. We found that the AAJT animals 
required a 64% smaller amount of fluids than the control group to keep a mean arterial pressure 
> 60 mm Hg. This was comparable to 3000 mL of crystalloid fluids. In a hypovolemic patient 
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with manifest or impending hemorrhage shock, such amounts of crystalloids only can be 
harmful. Considering that zone III REBOA and the AAJT are comparable regarding 
indications, we showed that the interventions are not equivalent as regards to fluid resuscitation 
requirements. In study two, the mean difference of crystalloid fluids to uphold a MAP > 60 
mm Hg were 2079 mL (95% CI 627-3530 mL) and importantly, four animals of six in the 
AAJT group sustained a MAP > 60 mm Hg with no additional crystalloids.  
After the uncontrolled bleeding with severe hypotension in study III, the animals required a 
mean total of 1600 mL RA in addition to inflation of the AAJT to restore MAP. This finding 
suggest that, in clinical scenarios with vessel injuries leading to rapid exsanguination, such as 
iliac and femoral artery injuries, even AAJT application solely may be insufficient in restoring 
critical proximal blood pressure.  
In study IV, the animals were transfused with shed blood (450 mL) in parallel with inflation of 
zone I REBOA simulating a clinical scenario with access to whole blood. This amount was not 
sufficient to prevent severe hypotension episodes, necessitating rescue occlusions, during the 
intermittent reperfusion intervals. The total proportion of successful three-minute reperfusions 
were 63%. We suggest that intermittent reperfusion during zone I REBOA therefore only 
should be performed with invasive blood pressure monitoring capabilities. Furthermore, the 
decreasing rate of successful balloon deflations (83% to 33%) during the 60-minute iREBOA 
protocol also implies that this is a volume dependent method to avoid hemodynamic instability. 
The amount of RA administered in the animals in study V was calculated by mean totals of 
mL/kg to compensate for differences in estimated total blood volume. The positive controls 
(hemorrhage and hemodilution) received a mean 103 mL/kg (range 92.3-117.5 mL/kg) to keep 
the acceptable MAP. The replacement of volume with crystalloid fluids only after a severe 
(60% of TBV) blood loss successfully established hemodilution coagulopathy, as shown by 








5.3 ORGAN EFFECTS 
 
5.3.1 Pulmonary 
The mechanical intra-abdominal pressure towards the diaphragm from the AAJT caused a 
significant decrease in pulmonary compliance and tidal volumes (TV). Ventilator settings were 
adjusted accordingly to maintain oxygenation (by FiO2 21%). REBOA did not cause any 
changes in pulmonary function demanding any changes in ventilator settings.   
 
5.3.2 Heart 
The hemodynamic changes associated with aortic occlusion caused a position dependent 
myocardial load. We showed a significant increase in troponin after continuous zone I aortic 
occlusion (666 ng/L) compared to intermittent balloon deflations (187 ng/L) in study IV. 
Furthermore, troponin increased during REBOA in both groups compared to baseline values 
and decreased after 60 min critical care with 32% (iREBOA) and 47% (cREBOA) respectively. 
These findings were in line with previous studies were pharmacological interventions on, 
cardiac selective, β–adrenergic receptors may have a therapeutic effect. Hence, the potential 
risk for myocardial infarction associated with thoracic aortic occlusion should be considered in 
patients during- and post intervention.  We did not observe any EKG changes associated with 
type-2 myocardial injury during the experiments.   
 
5.3.3 Liver and intestine 
Microscopic signs of ischemic injuries were detected by focal necrosis around the central 
hepatic vein and small bowel necrosis after 240 min AAJT application. Obvious signs of 




Figure 16. Post mortem laparotomy revealed ischemic bowel injury after 240 min AAJT application which was 
not observed after 60 min. Histologic examination confirmed bowel necrosis.  
 
5.3.4 Kidney 
No microscopic signs of kidney injury were detected after AAJT intervention. CT 
examinations of the AAJT animals showed bilateral contrast charging in the kidneys, with 
hydro nephrosis and hydro ureters developing during prolonged application, suggesting 
remaining renal perfusion, urine production and supra vesical obstruction. Prolonged AAJT 
application was associated with significantly increased myoglobin after reperfusion 
demonstrating rhabdomyolysis. Recognizing that kidney injury, and subsequent renal failure, 
can develop for up to seven days after trauma and exposure to toxic metabolites, the absence 
of acute tubular necrosis in microscopy-specimens should be carefully interpreted. Intermittent 
balloon deflations during zone I REBOA had a beneficial impact on urine output and 
restoration of renal blood flow implicating that mitigation of 60 min ischemia was beneficial, 
while the renal blood flow response did not correspond to restored aortic influx. P-Creatinine 
showed a two-fold increase after 60 min cREBOA compared to a half in iREBOA. Although 
this difference between groups did not reach statistical significance. After 60 min critical care, 





Decreased hematocrit (hct) and hypothermia were associated with cumulative crystalloid 
infusion >2000 mL (I-II, V). In contrast, AAJT application was associated with an increase in 
hematocrit and core temperature. The significant differences in hct is likely explained by the 
proximal pooling of blood volume after AAJT application (I-II) which caused an extravascular 
shift of plasma in combination with hemodilution in the animals receiving larger amounts of 
crystalloids. After class II hemorrhage (I-II), pH remained within physiologic range during 
zone III aortic occlusion. Lactate increased (3-7 mmol/L) with a corresponding drop in base 
excess (+5-0) after hemorrhage and further during aortic occlusion with no differences between 
devices. Zone I aortic occlusion was associated with increased lactate and lower pH than zone 
III interventions. Interestingly, lactate levels were equal between proximal arterial- and renal 
vein blood. This implies 1) a multi organ ischemia and 2) a venous communication allowing 
for open distribution along the concentration gradient. In study V, the animals subjected to 
trauma with hemorrhage and severe hemorrhage only (positive controls) showed a significant 
increased lactate and lower pH. Arterial oxygenation was within physiologic range in all 
animals with standard ventilatory settings in the experiments during the intervention phases. 
Hypoxia were seen in the animals subjected to polytrauma and respiratory acidosis due to the 
limited ventilation.   
 
5.3.6 Common femoral artery dimensions  
In study three we assessed the feasibility of transition from AAJT to zone III REBOA. This 
procedure may be an alternative for continued care of patients resuscitated with the AAJT in 
the prehospital environment, by enabling surgery with maintained bleeding control and 
hemodynamic stability. A challenging step for REBOA insertion is vascular access to the 
femoral artery. We showed that femoral artery dimensions decreased with a mean 52% after 
hemorrhage and AAJT application and further that the pulsations (helpful for identifying the 
artery) disappeared with AAJT application. Surgical capability of femoral artery access may 




Figure 17. The major decrease in femoral artery dimensions occurred after the class IV hemorrhage but was 
further aggregated following aortic occlusion by the AAJT.  
 
Figure 18. Preconditions for percutaneous arterial access (ultrasound) in a 60 kg pig at (a) BL: 5.04 mm, SBP 
110 mm Hg; (b) 40 % blood-loss:3.33 mm, SBP 15 mm Hg; (c) 30 min AAJT: 1.52 mm, SBP 54 mm Hg. 
Measurements indicated by the dotted blue line between the yellow and blue marks.  
 
5.4 REPERFUSION INJURY 
We quantified reperfusion injury by metabolic acidosis, vasopressor requirements and in study 
IV measurements of renal vein PCO2. Reperfusion after aortic occlusion was associated with 
considerable physiologic effects.  All animals showed a sharp decrease in pH and lactate levels 
increased to between 8-12 mmol/L. Noteworthy, the lactate levels were not increased after 
prolonged AAJT intervention and peak levels were similar during 60 versus 240 min 
intervention. Infra renal aortic occlusion was associated with milder reperfusion injury which 
was expected, however this effect was observed even when comparing 240 min of zone III 
occlusion with 60 min zone I. Intermittent reperfusion during zone I REBOA resulted in 
decreased ischemic time and milder reperfusion injury as reflected by all variables. In study I, 
potassium levels (K+) approximated 7 mmol/L which is associated with risk for lethal cardiac 
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arrhythmia. Peak levels did not differ between 60- and 240 min application times, however, 
after 30 min reperfusion, K+ returned to baseline levels after 60 min application but showed no 
trend towards normalization after prolonged application. In study IV, significantly higher doses 
of norepinephrine were required to maintain central blood pressure. 
 
5.5 COAGULATION TESTS 
Physiologic preconditions, as depicted in figure 19, associated with coagulopathy after 
trauma were effectively induced in the polytrauma and positive control groups according to 
the protocol.  
 
Figure 19. Systemic effects of the different trauma modalities (a-f, i). Hemorrhage and resuscitation fluid (RA) 
volume in the groups pulmonary contusion, positive controls and polytrauma (g-h). Comparisons were made with 
negative controls at the corresponding time. *p<0.05, **p<0.01, ***p<0.005, ****p<0.001, *****p<0.0001.  
Deranged coagulation, as detected by ROTEM, a decrease in coagulation factors (platelets; 
prothrombin (fII), and fibrinogen (fI) and aPC) and an increased D-dimer was established by 
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the polytrauma model introduced in study V. The positive control group with hemodilution 
after 6180 mL crystalloids following a 2358 mL hemorrhage also displayed an increased 
PT(INR). The polytrauma model consequently established coagulopathy due to a negative 
impact in both primary hemostasis and plasma coagulation. 
  
Figure 20. Principal component analysis of ROTEM presenting pathologic coagulation profiles in both 
polytrauma and positive control groups (visualized by the lines outside the dotted ring representing the 95% CI). 
Each dot represents an individual animal at a specific time point and the dots for the animal are connected with a 










Every health-care worker will encounter bleeding patients at some point during their career. 
Reflecting upon the fact that leakage of fluids from a system in almost any circumstance is 
fundamentally dealt with either by compression or wrapping directly to site of outflow or by 
upstream control of inflow to the damaged pipe, the invention of tourniquets and REBOA 
seems logical. Quite a few medical treatments used today were often preceded by historical 
interventions that sometimes were abandoned, not because they were proven useless, but rather 
due to lack of technical refinement and unexpected physiological consequences. This is 
certainly true regarding truncal tourniquets like the AAJT and even for endovascular 
techniques such as REBOA. This thesis has the privilege to discuss the fusion of ancient 
medical problems and their proposed solutions with the understanding of modern medicine. 
Further, the results of our studies may have direct implications for management of severely 
injured patients. This thesis shows that the application of today’s technical possibilities and 
physiological knowledge can revitalize historical treatments.  
The overall aim of this thesis was to provide physiological data on novel mechanical hemostatic 
adjuncts to facilitate their implementation into clinical practice and to contribute to the 
important research area of acute traumatic coagulopathy. We have contributed to the future 
management and possible rescue of severely injured patients with massive hemorrhage that 
historically, and today do not survive. We have investigated the efficacy and safety of a novel 
abdominal aortic tourniquet and to a certain extent novel aspects on the use of REBOA. 
Furthermore, we have provided new knowledge of the porcine research model for studies on 
the significantly important area of coagulation dysfunction associated with trauma. The 
establishment of a possible research model to enhance the understanding of TIC by use of 
viscoelastic tests that can be performed bedside, can possibly contribute to the understanding 
of the pathophysiology and development of new treatment options.     
The porcine animal model used in this thesis is robust and comparable to the bulk of literature 
in the field of research addressing hemorrhage shock and trauma. In the studies of this thesis 
we used the two principally different ways of induction of hemorrhage shock by controlled or 
uncontrolled hemorrhage. Both was successful in achieving the desired amount of blood loss 
and state of shock. Numerous ways of inducing hemorrhage shock have been described and it 
seems likely that no single method can be regarded as a golden standard. Instead, each should 
be looked at in the context of the research aims of the study. In essence, the combination of a 
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tissue injury and hemorrhage from the same location may reduce bias from instrumentational 
blood loss in simulated rates and from different anatomical areas. In study III-IV this was aimed 
at by the surgical exposure and transection of the femoral artery, a model injury for use of the 
AAJT and zone III REBOA. Importantly however, the results of these studies may not be 
transferrable to humans due to unexpected differences in response to trauma and hemorrhage 
(vascular constriction and mechanistic differences in hemostasis and coagulation) between 
swine and humans. Thus, the important aspect of maintained hemorrhage control should be 
carefully read.  In total, 60 animals were used in this thesis with a survival rate of 93%. This 
implies a robust and reproducible model in the context of potentially lethal hemorrhage and 
polytrauma, but also raises some concerns with the methodology. In studies I and IV we were 
not able to show any survival benefit in the primary outcome. It is possible that these studies 
were underpowered due to the small sample sizes yielded from the a priori calculations which 
were partly based on previously published external data.  This underlines the importance of 
hypothesis development in small-scale animal research models.  
The level of AO is fundamental for its physiological consequences as generally outlined in this 
thesis. In study I the finding of consistent infra-renal (zone III) AO by the AAJT was important 
with regards to the tolerance of application as well as the comparability with REBOA in study 
II-III. A possibly overlooked implication of the AAJT in this thesis (and the majority of reports 
of the AAJT) is the respiratory consequences. Endotracheal intubation and positive pressure 
ventilation is a potentially harmful intervention that should be avoided if possible in 
hypovolemic patients. On the other hand, the mechanical ventilation may have masked 
important aspects of respiratory function during application.  
Anaesthetic management of the animals in hemorrhage shock research is fundamental, and 
surprisingly often not discussed in detail, in terms of the interference with the biological 
response to trauma and hemorrhage. Anaesthesia of the pigs in the hemorrhage shock literature 
is generally maintained with inhaled agents such as isoflurane. This affects both baseline 
hemodynamic variables and the response to hemorrhage and trauma. We consistently used 
ketamine as the principal anaesthetic agent with adjuvant benzodiazepines and fentanyl in 
accordance with the ethical permit. This strategy both resembles the likely anaesthetic 
management of human patients in situations of hypovolemic shock and introduces less bias to 
the animal model by reduced interference with autonomously sympathetic-mediated responses 
to trauma and hemorrhage.   
We have shown that the previously reported correlation mismatch between aortic flow rate and 
aortic branch vessel flow in part may be explained by IRI. As indicated by the peak levels of 
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metabolic variables and clearance rate we confirmed that IRI is developing in a dose-effect 
relationship to ischemic time and level of AO. The milder reperfusion injury after zone III AO 
is logically explained by the higher tolerance to ischemia by the skeletal muscles in the lower 
extremities than abdominal organs.  
A major limitation of this thesis (and many other animal models in trauma research) is the 
general lack of longer post-intervention observation times and lack of functional outcome 
assessment. Studies have been conducted underlining the benefits of such methodology if 
ethically possible (162). This is especially limiting study IV were development of AKI could 
not fully be assessed due to the definition and the fact that it may develop up to 7 days after 
trauma and therefore not were detected. However, indices of organ function such as urine 
output and significantly higher return of RBF were indicative of the possibility to mitigate IRI 
by efforts to allow circulation to distal organs to some extent during AO. The possible 
mechanism behind this observation may be the combination of low grade oxygenation and 
avoidance of accumulating total hypoxic conditions and decreasing the impact of recirculation 
of large amounts of ischemic metabolites after uninterrupted AO.  
The possibility to detect TIC by ROTEM in pigs showed that this assay may be useful in 
parallel with its beneficial use in clinical scenarios. The traditional diagnostic criteria of TIC 
(using the platelet derived variables collected from plasma) has not yet been replaced by 
viscoelastic parameters.  PCA is a computational model for analysing data sets with high 
dimensionality with preservence of information that can be presented in a way that is easier to 
interpret. In study V, PCA was used to combine all 16 parameters of ROTEM for each time-
point of measurement into one for all animals (BL, 20 120 minutes). We were not able to assess 
the individual components of the polytrauma model, including systemic inflammatory response 
from LPS infusion, in relation to the development of TIC in our animal model. However, as an 
initial study it showed promise as a “proof of concept” and further studies may include PCA of 
ROTEM data to elucidate more specific contributions from each component used for inducing 
TIC. We showed a decrease in coagulation factors and aPC and an increased D-dimer after 
polytrauma indicating that the model includes the contribution of both disrupted clot-formation 
and fibrinolysis which are necessary for TIC.  
Finally, the possible implementation of results from our studies conducted on laboratory 
animals into clinical practice warrants discussion. The limitations of the experimental work and 
its conclusions must be thoroughly considered and clearly identified to avoid inappropriate or 
excessive use of potentially harmful procedures in clinical practice, this includes both too much 





In this thesis we were able to confirm the efficacy of novel, mechanical hemostatic adjuncts 
such as the AAJT and REBOA for hemorrhage control in severe NCH. We further elucidated 
important aspects of fluid resuscitation in conjunction with these adjuncts. We were not able 
to determine a specific application time beyond which irreversible organ damage develops with 
AAJT application, however, we did provide novel and important findings of specific ischemic 
organ injuries associated with the device. We have shown that the AAJT and REBOA can be 
used to maintain hemostasis in the same patient during different levels of care and also provided 
important procedural and physiological aspects of changeover between the interventions. We 
have also confirmed that management strategies such as intermittent reperfusion during aortic 
occlusion may impact the dose-dependent development of ischemic reperfusion injury and 
direct organ effects of REBOA.   
I The AAJT causes ischemic injuries to abdominal organs beyond 60-minute 
application, including the small intestine and liver, both due to mechanical 
compression and decreased visceral perfusion. Further, the intra-abdominal 
pressure causes decreased pulmonary compliance. Release of the AAJT should 
only be performed with the capability to counteract severe hypotension and 
metabolic acidosis.  
II In comparison with the AAJT, resuscitation with zone III REBOA may require 
fluids to restore hemodynamic function, comparable to 2000 mL of crystalloids.  
III  Percutaneous access to the common femoral artery for REBOA insertion may be 
challenging after severe hemorrhage, and further complicated with external AO 
by the AAJT. The procedure was performed with preserved hemostasis but 
resulted in mild hypotension.  
IV Intermittent REBOA was associated with significant hemodynamic fluctuations 
including decreased heart rate and blood pressure with associated lower levels of 
troponin I, used as an indicator of cardiac injury. We confirmed that aortic blood 
flow during hemorrhage shock and REBOA deflation did not correlate with renal 
artery blood flow. However, the degree of renal perfusion during balloon 
deflations resulted in increased urine output and thus improved organ function.  
V We established a porcine research model fulfilling the Berlin criteria of 
polytrauma and introduced principal component analysis for viscoelastic tests 
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(ROTEM), which may improve the detection and differentiation of TIC-




8 POINTS OF PERSPECTIVE 
 
Prospectively collected human data are necessary to consolidate the findings from the 
increasing data gathered from translational research models. Such efforts are underway and by 
the formation of the AORTA registry in the US, a solid platform for data collection has been 
built.  With the rapid development of endovascular techniques and adjuncts it is likely that 
REBOA in clinical practice will be seen as a more dynamic tool for controlling hemorrhage 
with increased focus on mitigation of IRI by pREBOA. This will also influence its use in the 
early phases of care including pre-hospital and battlefield environments.  
The major findings in the present thesis that may be transferrable to clinical management of 
human patients are considered as follows: 
• AAJT and REBOA are effective for control of severe NCH and should be further 
considered for prehospital use. 
• The AAJT may be considered as a point of care intervention due to the ease of use and 
absence of malfunction. 
• A 60 min application time should not be exceeded with the AAJT. 
• Deflation of the AAJT or REBOA balloon should not be performed in the prehospital 
environment. 
• Patients resuscitated with the AAJT should be considered for zone III REBOA in higher 
levels of care and the procedure can be performed safely with caution regarding 
hypotension.  
• Zone III REBOA should be assisted with fluid resuscitation to restore effective 
proximal circulation after massive hemorrhage.  
• Weaning from AO should be monitored several hours with regards to acidosis, 
electrolyte abnormalities, distal perfusion conditions including development of 
compartment syndrome after IRI.  
• Further refinement of balloon catheters or timings in protocols for intermittent 
reperfusion should be explored. 
• Intermittent reperfusion during REBOA may be considered in relatively stable patients 
to counteract IRI and possibly to decrease the risk of organ damage to the heart and 
kidneys.  
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